Adagene Inc. Files 6-K with Q2 2025 Financial Updates
Ticker: ADAG · Form: 6-K · Filed: 2025-08-12T00:00:00.000Z
Sentiment: neutral
Topics: financial-update, balance-sheet, sec-filing
TL;DR
Adagene dropped its Q2 2025 financials on 8/12 - check the balance sheet for capital and retained earnings.
AI Summary
Adagene Inc. filed a 6-K report on August 12, 2025, detailing its financial position as of June 30, 2025. The filing includes balance sheet information for the periods ending June 30, 2025, December 31, 2024, and June 30, 2024, with specific line items such as Additional Paid-In Capital, Common Stock, Retained Earnings, and Accumulated Other Comprehensive Income.
Why It Matters
This filing provides investors with an update on Adagene's financial health and capital structure, crucial for assessing its ongoing operational capacity and investment potential.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing balance sheet details, not indicating new material events or significant changes.
Key Players & Entities
- Adagene Inc. (company) — Filer of the report
- August 12, 2025 (date) — Filing date
- June 30, 2025 (date) — Reporting period end date
FAQ
What is the filing date of this 6-K report?
The filing date of this 6-K report is August 12, 2025.
What period does the financial information in this filing primarily cover?
The financial information primarily covers the period ending June 30, 2025, with comparative data for December 31, 2024, and June 30, 2024.
What are some of the key balance sheet components reported by Adagene Inc.?
Key balance sheet components reported include Additional Paid-In Capital, Common Stock, Retained Earnings, and Accumulated Other Comprehensive Income.
What is the fiscal year end for Adagene Inc.?
The fiscal year end for Adagene Inc. is December 31.
What is the SEC file number for Adagene Inc.?
The SEC file number for Adagene Inc. is 001-39997.
From the Filing
0001410578-25-001700.txt : 20250812 0001410578-25-001700.hdr.sgml : 20250812 20250812160601 ACCESSION NUMBER: 0001410578-25-001700 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250812 DATE AS OF CHANGE: 20250812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39997 FILM NUMBER: 251206625 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 6-K 1 adag-20250812x6k.htm 6-K Adagene Inc._2025-06-30 2025-06-30 --12-31 Q2 2025 0001818838 false 0001818838 2025-01-01 2025-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001818838 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001818838 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001818838 us-gaap:RetainedEarningsMember 2025-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001818838 us-gaap:RetainedEarningsMember 2024-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2024-06-30 0001818838 us-gaap:RetainedEarningsMember 2024-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001818838 us-gaap:TreasuryStockCommonMember 2023-12-31 0001818838 us-gaap:RetainedEarningsMember 2023-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001818838 us-gaap:CommonStockMember 2025-06-30 0001818838 us-gaap:CommonStockMember 2024-12-31 0001818838 us-gaap:CommonStockMember 2024-06-30 0001818838 us-gaap:CommonStockMember 2023-12-31 0001818838 srt:MinimumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2025-01-01 2025-06-30 0001818838 srt:MaximumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2025-01-01 2025-06-30 0001818838 srt:MinimumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2024-01-01 2024-06-30 0001818838 srt:MaximumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2024-01-01 2024-06-30 0001818838 2023-01-01 2023-12-31 0001818838 us-gaap:ShareBasedPaymentArrangementNonemployeeMember adag:PerformanceIncentivePlan2021Member 2025-05-01 2025-05-31 0001818838 us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2025-01-01 2025-06-30 0001818838 us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2024-01-01 2024-06-30 0001818838 adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-07 2022-01-07 0001818838 adag:SanofiAgreementMember 2025-01-01 2025-06-30 0001818838 adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember 2025-01-01 2025-06-30 0001818838 adag:ExelixisIncAgreementMember 2025-01-01 2025-06-30 0001818838 adag:SanofiAgreementMember 2024-01-01 2024-06-30 0001818838 adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember 2024-01-01 2024-06-30 0001818838 adag:ExelixisIncAgreementMember 2024-01-01 2024-06-30 0001818838 adag:DragonBoatBiopharmaceuticalShanghaiLimited